Company intelligence / Profile preview
Chai Therapeutics
San Francisco, CA, USAchaidiscovery.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Chai-2 achieves double-digit experimental success rates (16% reported) in de novo antibody design—a 100-fold improvement over previous computational methods.[1][3][5] Over 86% of full-length monoclonal antibodies designed show strong developability profiles comparable to therapeutic antibodies, with atomic-level structural predictions matching experimental determinations.[1][5]
- Therapeutic areas
- ImmunologyOtherNeurologyPulmonologyMetabolic Disorders
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
select pharma partners
Beyond the preview
Go deeper on Chai Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chai Therapeutics.